Can MRI outsmart blood tests for prostate cancer?

NCT ID NCT03784924

Recruiting now Diagnosis Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study enrolls 950 men with suspected but undiagnosed prostate cancer who are scheduled for a biopsy. Researchers will compare the accuracy of prostate MRI against a panel of blood and urine biomarkers (PCA3, PSA, TMPRSS2:ERG) in detecting clinically significant prostate cancer (Gleason 7 or higher). The goal is to determine which method is better at identifying aggressive cancers in the initial biopsy setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRI prostate (diagnostic test) and laboratory biomarkers (PCA3, PSA, TMPRSS2:ERG)
What this could lead to: If successful, this could show that MRI is better than current biomarker tests at finding aggressive prostate cancer, helping men avoid unnecessary biopsies.
What could go wrong: This is an observational study, not a treatment trial. Results may not change practice immediately, and MRI may not prove superior to biomarkers in all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pleomorphic adenoma prostate cancer Salivary Gland Adenoma, Pleomorphic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER PSA

Contacts and locations

Locations

University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.